hotspot -WSS

hotspot

author：comprehensive 2025-10-02 00:43:27 - browse：1

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Carbon Health diabetes program, a test of data

WSS

DeSantis can now import cheaper drugs. But will Biden get credit?

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

FDA reorg will put new emphasis on investigations, sources say

Healthy food access boosts outcomes in two studies

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

In Memoriam: Notable people who died in 2023

Health and fitness trackers are measuring the wrong things

At least 13 dead in Texas as scorching temps continue

Type 2 diabetes prevention programs work at large scale: study

Novavax promises a turnaround & Lilly roils the obesity market

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

In Memoriam: Notable people who died in 2023

Health and fitness trackers are measuring the wrong things

At least 13 dead in Texas as scorching temps continue

Cancer diagnosis changes perspective doctor, former hospital CEO

Wikipedia

Doulas covered by Medicaid under New York's new plan

A letter from the executive editor: STAT UnitedHealth investigation

What health policies could hitch a ride on a spending bill?

JPM 2024: Verve Therapeutics looks to mainstream genome editing

After decades in use, heart stents finally beat placebo

New menopause drug shows promise in relief for hot flashes

leisure time

hotspot

leisure time

hotspot